AAP
MNPR icon

Arax Advisory Partners’s Monopar Therapeutics MNPR Stock Holding History

Arax Advisory Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278 Buy
+3
New +$186 ﹤0.01% 5065
2025
Q4 		– Sell
-14
Closed -$1.14K – 4363
2025
Q3 		$1.14K Buy
+14
New +$626 ﹤0.01% 3229

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Arax Advisory Partners's MNPR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 3 shares worth $278. The stake represents ﹤0.01% of the portfolio and ranks #5065 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MNPR as recently as Q3 2025.

Arax Advisory Partners first reported a position in MNPR in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.14K in Q3 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Arax Advisory Partners held 3 shares of Monopar Therapeutics worth $278 as of Q2 2026.
  • Monopar Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5065 holding.
  • Arax Advisory Partners first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Monopar Therapeutics position peaked at $1.14K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.